Cerebral Amyloid Angiopathy in Alzheimer Disease Continuum: Prevalence and Clinical Relevance in a Biomarker-Defined Memory Clinic Cohort

BACKGROUND AND OBJECTIVES: Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer disease (AD), yet the prevalence and clinical significance of comorbid CAA among cognitively impaired individuals on the AD continuum remain unclear. We aimed to determine the frequency of probable CAA (Boston criteria v2.0) in a memory-clinic cohort of symptomatic amyloid-positive individuals and to compare demographic, clinical, cognitive, and biomarker profiles between those with and without comorbid probable CAA. METHODS: We conducted a retrospective cohort study at the Geneva Memory Center including amyloid-positive patients confirmed by CSF or amyloid PET. Participants meeting the Boston criteria v2.0 for probable CAA were classified as AD-probable CAA, whereas those with possible or no CAA were classified as AD-nonprobable CAA. Group differences were assessed using standard parametric and nonparametric tests, linear mixed-effects models for cognitive trajectories, logistic regression for cerebral microbleed (CMB)-CSF biomarker associations, and voxel-wise Statistical Parametric Mapping for regional amyloid PET differences. RESULTS: < 0.05). DISCUSSION: More than one-quarter of amyloid-positive patients fulfilled the Boston criteria v2.0 for probable CAA. Probable CAA was not associated with a distinct clinical presentation or trajectory of cognitive decline. Higher cortical amyloid PET uptake in probable CAA and the association of lower CSF Aβ42 with lobar CMB burden suggest more prominent cerebral amyloidosis in this population. The binary probable CAA label may therefore reflect greater amyloid burden without necessarily delineating a clinically distinct subgroup within the AD continuum. Marker-specific approaches targeting cortical superficial siderosis and high lobar CMB burden may prove more informative.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-11-12
DOI
https://doi.org/10.1212/wnl.0000000000218738
Citations
1
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
article
Field-Weighted Citation Impact
3.02
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cerebral Amyloid Angiopathy in Alzheimer Disease Continuum: Prevalence and Clinical Relevance in a Biomarker-Defined Memory Clinic Cohort

Fabrizio Piazza, Karl‐Olof Lövblad, Cecilia Boccalini, Augusto J. Mendes et al.
1 citations
Neurology
Intracerebral and Subarachnoid Hemorrhage Research
3.02
article

Cerebral Amyloid Angiopathy in Alzheimer Disease Continuum: Prevalence and Clinical Relevance in a Biomarker-Defined Memory Clinic Cohort

Fabrizio Piazza, Karl‐Olof Lövblad, Cecilia Boccalini, Augusto J. Mendes, Max Scheffler, Valentina Garibotto, Giovanni Battista Frisoni, Aurélien Lathuilière, Miguel A. Frias, Federica Ribaldi, Christian Chicherio, Hadrien M. Lalive, Ilse Kern, Elif Harput, C. Wang
article en
1 citations

Abstract

BACKGROUND AND OBJECTIVES: Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer disease (AD), yet the prevalence and clinical significance of comorbid CAA among cognitively impaired individuals on the AD continuum remain unclear. We aimed to determine the frequency of probable CAA (Boston criteria v2.0) in a memory-clinic cohort of symptomatic amyloid-positive individuals and to compare demographic, clinical, cognitive, and biomarker profiles between those with and without comorbid probable CAA. METHODS: We conducted a retrospective cohort study at the Geneva Memory Center including amyloid-positive patients confirmed by CSF or amyloid PET. Participants meeting the Boston criteria v2.0 for probable CAA were classified as AD-probable CAA, whereas those with possible or no CAA were classified as AD-nonprobable CAA. Group differences were assessed using standard parametric and nonparametric tests, linear mixed-effects models for cognitive trajectories, logistic regression for cerebral microbleed (CMB)-CSF biomarker associations, and voxel-wise Statistical Parametric Mapping for regional amyloid PET differences. RESULTS: < 0.05). DISCUSSION: More than one-quarter of amyloid-positive patients fulfilled the Boston criteria v2.0 for probable CAA. Probable CAA was not associated with a distinct clinical presentation or trajectory of cognitive decline. Higher cortical amyloid PET uptake in probable CAA and the association of lower CSF Aβ42 with lobar CMB burden suggest more prominent cerebral amyloidosis in this population. The binary probable CAA label may therefore reflect greater amyloid burden without necessarily delineating a clinically distinct subgroup within the AD continuum. Marker-specific approaches targeting cortical superficial siderosis and high lobar CMB burden may prove more informative.

NeurologyVol. 107(11)
University of Geneva (CH), University Hospital of Geneva (CH), University of Milano-Bicocca (IT)
Good health and well-being
Openalex Percentile: Top 16%
Intracerebral and Subarachnoid Hemorrhage Research
3.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon